Granted Patent
B2
US 11,001,603 · App. 17/009,590 · Granted May 11, 2021
Modulators of 5′-nucleotidase, ecto and the use thereof
Inventors:
Laurent Pierre Paul Debien (San Francisco, CA); Juan Carlos Jaen (Burlingame, CA); Jaroslaw Kalisiak (Mountain View, CA); Kenneth V. Lawson (San Francisco, CA); Manmohan Reddy Leleti (West San Jose, CA); Erick Allen Lindsey (Fremont, CA); Dillon Harding Miles (Berkeley, CA); Eric Newcomb (Menlo Park, CA); Jay Patrick Powers (Pacifica, CA); Brandon Reid Rosen (San Mateo, CA); Ehesan Ul Sharif (Menlo Park, CA)
Assignee:
ARCUS BIOSCIENCES, INC.
C07H19/23A61K31/70A61K31/706A61K31/7052A61K31/7064A61K31/7076A61K45/06C07F9/6561C07F9/65616C07H19/04C07H19/14C07H19/16C07H19/20C07H19/207
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Compounds that modulate the conversion of AMP to adenosine by 5′-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5′-nucleotidase, ecto is also provided.
Claims (2)
1. A compound having the formula
or a pharmaceutically acceptable salt thereof.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 2, 2020
From: DEBIEN, LAURENT PIERRE PAUL; JAEN, JUAN CARLOS; KALISIAK, JAROSLAW; LAWSON, KENNETH V.; LELETI, MANMOHAN REDDY; LINDSEY, ERICK ALLEN; MILES, DILLON HARDING; NEWCOMB, ERIC; POWERS, JAY PATRICK; ROSEN, BRANDON REID; SHARIF, EHESAN UL
To: ARCUS BIOSCIENCES, INC.
Reel/Frame 053679/0252 →
Continuity (5)
Provisional Application
62276564
· Jan 8, 2016
Provisional Application
62324077
· Apr 18, 2016
Cited By (5)